Partners

abiogen 380

Abiogen Pharma commercializes Binosto® in Italy under EffRx license.

adcock ingram

EffRx has licensed the distribution and commercialization of Binosto® in South Africa, Namibia, Botswana, Swaziland, Lesotho, Zimbabwe, Kenya and Ghana in partnership with Adcock Ingram Ltd.

ahngook

EffRx has licensed the distribution and commercialization of Binosto® in South Korea to Ahngook Pharmaceutical.

ANDRUS

EffRx has licensed the distribution and commercialization of Binosto® in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan in partnership to Andrus, Ltd.

ASTRONG

EffRx Pharmaceuticals SA has licensed the distribution and commercialization of Binosto® in Taiwan to A-Strong Co., Ltd.

ATRAL

Labóratorios Atral commercializes Binosto® in Portugal, Angola, Mozambique, Cape Verde, Guinea-Bissau, Sao Tome and Principe under EffRx license.

CLONMEL 380x120

Clonmel Healthcare Limited has agreed to commercialize Binosto® in Ireland under EffRx Pharmaceuticals license. Along with Thornton & Ross and Internis, Clonmel belongs to the STADA group

COTE ORPHAN 380x120

Dr. Timothy Coté and his team are dedicated to providing expert advice that enables industry leaders to successfully navigate the orphan regulatory landscape. Coté Orphan serves as EffRx’s authorized representative towards US-FDA during the EX404 program.

EXPANSCIENCE 380x120

Laboratoires Expanscience is a well established French pharmaceutical company with strong footprint in Rheumatology and Dermatology. EffRx has licensed the distribution and commercialization of Binosto® in France to Expanscience Laboratoires.

GALENICA 380x120

EffRx has licensed the distribution and commercialization of Binosto® in Greece to Galenica S.A.

HIKMA 380x120

EffRx has licensed the distribution and commercialization of Binosto® in 18 Middle Eastern and African countries to Hikma Phamaceuticals.

INTERNIS 380

Internis Pharmaceuticals Ltd has agreed to commercialize Binosto® in the United Kingdom under EffRx Pharmaceuticals license.

KADMON 380

EffRx has established a strong partnership with Kadmon Pharmaceuticals to develop and commercialize certain therapies for liver indications.

LABATEC 380x120

EffRx has licensed the distribution and commercialization of Binosto® in Switzerland to Labatec-Pharma S.A.

lacer 380

Lacer commercializes Binosto® in Spain under EffRx license.

MERCK 380x120

EffRx licensed intellectual property from Merck Worldwide, a leading research-drive healthcare company to create its buffered, effervescent formulation of Binosto® for the treatment of osteoporosis.

MISSION 380x120

EffRx has established a strong partnership with Mission Pharmacal to develop and commercialize our lead product Binosto® in USA.

T&R 380

Thornton & Ross is one of the largest OTC pharmaceutical manufacturers in the UK. Internis is the leading manufacturer and supplier of prescription Vitamin D medicines. Both companies are part of the STADA group. EffRx has licensed the distribution and commercialization of Binosto® in the United Kingdom to Thornton & Ross / Internis.

ZUELLIG 380

EffRx has licensed the distribution and commercialization of Binosto® in South East Asia to Zuellig Pharma Asia Pacific Limited.